CA2796561C - Genetic factors associated with inhibitor development in hemophilia a - Google Patents

Genetic factors associated with inhibitor development in hemophilia a Download PDF

Info

Publication number
CA2796561C
CA2796561C CA2796561A CA2796561A CA2796561C CA 2796561 C CA2796561 C CA 2796561C CA 2796561 A CA2796561 A CA 2796561A CA 2796561 A CA2796561 A CA 2796561A CA 2796561 C CA2796561 C CA 2796561C
Authority
CA
Canada
Prior art keywords
individual
fviii
snp
factor viii
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2796561A
Other languages
English (en)
French (fr)
Other versions
CA2796561A1 (en
Inventor
Erik Berntorp
Jan Astermark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA3050896A priority Critical patent/CA3050896C/en
Publication of CA2796561A1 publication Critical patent/CA2796561A1/en
Application granted granted Critical
Publication of CA2796561C publication Critical patent/CA2796561C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2796561A 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a Active CA2796561C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3050896A CA3050896C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32660210P 2010-04-21 2010-04-21
US61/326,602 2010-04-21
PCT/EP2011/056471 WO2011131774A1 (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3050896A Division CA3050896C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Publications (2)

Publication Number Publication Date
CA2796561A1 CA2796561A1 (en) 2011-10-27
CA2796561C true CA2796561C (en) 2019-09-17

Family

ID=43983253

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2796561A Active CA2796561C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a
CA3050896A Active CA3050896C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3050896A Active CA3050896C (en) 2010-04-21 2011-04-21 Genetic factors associated with inhibitor development in hemophilia a

Country Status (7)

Country Link
US (3) US9637789B2 (https=)
EP (2) EP2730663B1 (https=)
JP (4) JP6058529B2 (https=)
AU (1) AU2011244228B2 (https=)
CA (2) CA2796561C (https=)
ES (1) ES2949953T3 (https=)
WO (1) WO2011131774A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
AU2011244228B2 (en) * 2010-04-21 2015-07-30 Jan Astermark Genetic factors associated with inhibitor development in hemophilia A
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
KR101774996B1 (ko) * 2016-06-23 2017-09-19 주식회사 녹십자지놈 혈우병 치료제의 효능 예측 마커 및 이의 용도
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JP4071277B2 (ja) 1993-11-12 2008-04-02 ピーエイチアールアイ・プロパティーズ・インコーポレーテッド 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット
AU710425B2 (en) 1995-12-18 1999-09-23 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
WO2008059009A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
AU2011244228B2 (en) * 2010-04-21 2015-07-30 Jan Astermark Genetic factors associated with inhibitor development in hemophilia A

Also Published As

Publication number Publication date
US9644239B2 (en) 2017-05-09
CA3050896A1 (en) 2011-10-27
EP2730663A3 (en) 2014-09-10
EP2730663B1 (en) 2023-03-22
JP2019180421A (ja) 2019-10-24
AU2011244228B2 (en) 2015-07-30
US20120065077A1 (en) 2012-03-15
AU2011244228A1 (en) 2012-11-08
CA2796561A1 (en) 2011-10-27
CA3050896C (en) 2023-01-24
ES2949953T3 (es) 2023-10-04
JP2015226551A (ja) 2015-12-17
JP6189904B2 (ja) 2017-08-30
EP2730663A2 (en) 2014-05-14
JP6568162B2 (ja) 2019-08-28
US9637789B2 (en) 2017-05-02
US20180016635A1 (en) 2018-01-18
JP2013529071A (ja) 2013-07-18
JP6058529B2 (ja) 2017-01-11
JP2017200491A (ja) 2017-11-09
EP2561090A1 (en) 2013-02-27
WO2011131774A1 (en) 2011-10-27
US20110312519A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
CA2796561C (en) Genetic factors associated with inhibitor development in hemophilia a
CN103865997B (zh) 高血压易感基因组的鉴定
AU2014203270B2 (en) Method of treating cancer
JP7729608B2 (ja) 膀胱癌治療におけるｂｃｇ膀胱内注入療法の治療効果を予測するためのバイオマーカー、方法、キット及びアレイ
AU2015249180B2 (en) Genetic factors associated with inhibitor development in hemophilia a
KR102443042B1 (ko) 직접경구용 항응고제 투여시의 출혈 부작용 예측용 snp 마커 및 이의 용도
US9447469B2 (en) Identification of genetic variants
HK1197923A (en) Genetic factors associated with inhibitor development in hemophilia a
HK1197923B (en) Genetic factors associated with inhibitor development in hemophilia a

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160413

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808